




RealRate

PROGRAMMING 2023

Bioregenx INC Rank 75 of 78





PROGRAMMING 2023

Bioregenx INC
Rank 75 of 78

The relative strengths and weaknesses of Bioregenx INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bioregenx INC compared to the market average is the variable Cost of Goods and Services Sold, increasing the Economic Capital Ratio by 4.8% points. The greatest weakness of Bioregenx INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 137% points.

The company's Economic Capital Ratio, given in the ranking table, is 27%, being 202% points below the market average of 228%.

| Input Variable | Value in 1000 USD | Output Variable | Value in 1000 USD |
|------------------------------------|-------------------|-----------------------------|-------------------|
| Assets, Current | 0.68 | Assets | 59 |
| Assets, Non-Current | 0 | Liabilities | 261 |
| Cost of Goods and Services Sold | 0 | Expenses | 120 |
| General and Administrative Expense | 0 | Revenues | 42 |
| Intangible Assets | 0 | Stockholders Equity | -202 |
| Lease Assets | 0 | Net Income | -78 |
| Lease Liability | 0 | Comprehensive Net Income | -117 |
| Liabilities, Current | 65 | BaseVar | 261 |
| Liabilities, Non-Current | 196 | ECR before LimitedLiability | -366% |
| Other Assets | 58 | Economic Capital Ratio | 27% |
| Other Compr. Net Income | -39 | | |
| Other Expenses | 120 | | |
| Other Liabilities | 0 | | |
| Other Net Income | 0 | | |
| Other Revenues | 42 | | |
| Property Plant and Equipment | 0 | | |
| Research and Development Expense | 0 | | |
| Selling Expense | 0 | | |